Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07868489 in pulmonary arterial hypertension
ISRCTN65235904Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing PF-07868489 with Placebo (2 arms). Primary endpoints: Incidence and severity of adverse events and serious adverse events, Change from baseline in vital signs and 3 more. Started Jun 2025; status: recruiting.
02
Drugs
PF-07868489
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on ISRCTN65235904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN65235904.